Silexion Therapeutics Corp 8-K

What Happened

• Silexion Therapeutics Corp (ticker: SLXN) filed a Form 8-K on March 25, 2026 (Item 5.02) announcing that the Board removed director Ilan Levin, effective immediately. The removal was adopted unanimously in writing by the other Board members pursuant to Article 28.7 of the Company’s Amended and Restated Articles of Association, as amended.

Key Details

• Date of filing: March 25, 2026 (Form 8-K, Item 5.02).
• Director removed: Ilan Levin; removal effective immediately on March 25, 2026.
• Method: Unanimous written determination by all other Board members under Article 28.7 of the Company’s Articles.
• The filing does not state a reason for the removal or identify any replacement director.

Why It Matters

• A change in the Board affects corporate governance and oversight; investors should note the reduction or change in Board composition and watch for further filings announcing any new director appointments or board committee changes. The 8-K contains no disclosure of financial impact or reasons for the removal, so any material implications will depend on subsequent Company disclosures.